L-Lactic Acid

L-Lactic Acid

SCHEMBL668437

CC(O)C(=O)[O-].CCCC[P+](CCCC)(CCCC)CCCC

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3

The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.54
CA2 P00918 5/20 0.52
DNM1 Q05193 2/20 0.48
NFKB1 P19838 3/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GPR84 Q9NQS5 1/20 0.41
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Lactic Acid SCHEMBL16008431 0.91 DNM1 (0.56) CA1CA2DNM1NFKB1GPR84
Cadaverine Tartrate SCHEMBL3678567 0.86 CA2 (0.52) CA1CA2DNM1NFKB1CYP3A4
Bicarbonate SCHEMBL1685163 0.85 DNM1 (0.57) CA1CA2DNM1NFKB1CYP3A4
Alanine SCHEMBL16289673 0.84 CA1 (0.52) CA1CA2DNM1NFKB1CYP3A4
Valine SCHEMBL669193 0.84 SLC7A5 (0.48) CA1CA2DNM1GPR84MAPK1
Acetic Acid SCHEMBL123876 0.83 DNM1 (0.55) CA1CA2DNM1NFKB1CYP3A4
Oxalic Acid SCHEMBL1052557 0.83 DNM1 (0.55) CA1CA2DNM1NFKB1CYP3A4
Acetic Acid SCHEMBL329012 0.83 DNM1 (0.55) CA1CA2DNM1NFKB1CYP3A4
Bicarbonate SCHEMBL5275078 0.83 DNM1 (0.55) CA1CA2DNM1NFKB1CYP3A4
Bicarbonate SCHEMBL5275073 0.83 DNM1 (0.55) CA1CA2DNM1NFKB1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117658802-A Method for preparing lactate by catalyzing alcoholysis of polylactic acid by ionic liquid 中国科学院化学研究所 2024-03-08 CN claimed
CN-117658794-A Method for preparing lactic acid by catalyzing polylactic acid hydrolysis through ionic liquid 中国科学院化学研究所 2024-03-08 CN claimed
CN-117623968-A Method for preparing N-substituted lactamide by catalyzing polylactic acid aminolysis with ionic liquid 中国科学院化学研究所 2024-03-01 CN claimed
EP-2174969-A1 RESIN COMPOSITION Ajinomoto Co., Inc. (JP) 2010-04-14 EP claimed
US-20090030158-A1 RESIN COMPOSITION AJINOMOTO CO., INC (JP) 2009-01-29 US claimed
CN-114450370-B Adhesive sheet 味之素株式会社 2025-01-28 CN disclosed
WO-2024242636-A1 APPARATUS AND METHOD FOR FORMING SEMI-CLATHRATE HYDRATES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2024-11-28 WO disclosed
CN-118544649-A Metal foil laminate for use in collector layer and method for producing same 味之素株式会社 2024-08-27 CN disclosed
CN-118438680-A Method for adhering adherend 味之素株式会社 2024-08-06 CN disclosed
CN-118344595-A Polydimethylsiloxane-containing bio-based polycarbonate copolymer and preparation method thereof 中国科学院成都有机化学有限公司 2024-07-16 CN disclosed
CN-116804109-A Resin composition and thermosetting adhesive sheet 味之素株式会社 2023-09-26 CN disclosed
CN-113646170-B Resin sheet with support 味之素株式会社 2023-05-30 CN disclosed
EP-2698393-A1 Resin composition Ajinomoto Co., Inc. (JP) 2014-02-19 EP disclosed
US-20130203602-A1 SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS DANMARKS TEKNISKE UNIVERSITET (DK) 2013-08-08 US disclosed
EP-2544664-A1 SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS Danmarks Tekniske Universitet (DK) 2013-01-16 EP disclosed
US-20120046244-A1 DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2012-02-23 US disclosed
WO-2011110662-A1 SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS DANMARKS TEKNISKE UNIVERSITET (DK) 2011-09-15 WO disclosed
WO-2010078300-A1 DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2010-07-08 WO disclosed
EP-2174969-A1 RESIN COMPOSITION Ajinomoto Co., Inc. (JP) 2010-04-14 EP disclosed
US-20090030158-A1 RESIN COMPOSITION AJINOMOTO CO., INC (JP) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203602-A1 SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS MIF, BMP2, BMP4 CA1 301/4885CA2 646/4885DNM1 4827/4885
US-20090030158-A1 RESIN COMPOSITION PPA1, PTGER1, TAF5 CA1 867/4885CA2 1595/4885DNM1 4194/4885
US-20120046244-A1 DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF SLC6A6, SLC10A2, CLK2 CA1 1519/4885CA2 176/4885DNM1 4027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.